ImmunoForge to Host Strategic Partnering Meetings During J.P. Morgan Healthcare Conference 2026

Focusing on global out-licensing of Phase 2 assets PF1801 and PF1804. Company to engage with global big pharma in San Francisco to accelerate U.S. clinical entry. SEOUL, South Korea, Jan. 1, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd. (Co-CEOs Sung-Min Ahn and Kiho Chang), a clinical-stage...

Read More